Palo Alto-based Greenstone Biosciences, Inc. and Intel Corporation have announced a strategic collaboration that brings one of the largest human induced pluripotent stem cell (iPSC) biobanks together with AI computing infrastructure, reflecting the growing convergence of digital biology, advanced computing, and next-generation preclinical drug development. Financial terms were not disclosed.
Under the agreement, Greenstone will contribute its human iPSC biobank, patient-derived organoids, population-scale genomic datasets, and expertise in New Approach Methodologies (NAMs), while Intel will provide Edge AI computing infrastructure, advanced data processing architecture, and AI-enabled analytics capabilities. The companies said the collaboration is intended to support identification of patient-specific drug response patterns, improve prediction of adverse drug effects, and enable analysis of large-scale cellular datasets generated through human-relevant disease models.
While semiconductor companies have long supported genomics, bioinformatics, and healthcare AI applications, a growing number are moving closer to the drug discovery process itself. Nvidia has struck partnerships focused on AI-driven drug discovery and biological foundation model development with companies including Recursion Pharmaceuticals and Qiagen, among others, while AMD has partnered with and invested in Absci to support generative AI-based therapeutic design. The Greenstone collaboration extends that trend into human-cell-based discovery platforms, where iPSC-derived models, organoids, and population-scale biological datasets are creating new computational demands. The partnership reflects a broader convergence of advanced computing infrastructure and experimental biology as drug discovery becomes increasingly data-intensive.
The collaboration also aligns with growing regulatory interest in NAMs. The FDA Modernization Act has encouraged adoption of human-relevant testing approaches that complement or reduce reliance on traditional animal models, increasing demand for both biological platforms and the computational infrastructure required to process the resulting data at scale.